CD8+ T cells (p = 0.014), macrophages (p = 0.012), neutrophil cells (p = 0.016), and YTHDF2 expression (p = 0) were both shown to be consistent with the treatment outcomes in RCC patients (Supplementary Table S3). The gene discussed is CD8A; the disease is renal cell carcinoma.